Indio (111in) Oxina Curium Pharma Spain

Indium-111 oxine, the active ingredient in Indio (111in) Oxina Curium Pharma Spain, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed to label white blood cells for imaging infection, inflammation and related conditions in patients undergoing nuclear medicine examinations.

GNH USA supplies Indio (111in) Oxina Curium Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Indium-111 oxine is used in nuclear medicine to visualize sites of infection and inflammation through labeled leukocyte imaging. - Infection detection: identifies acute bacterial infections and helps locate abscesses. - Inflammatory disease imaging: visualizes active inflammatory lesions such as vasculitis. - Fever of unknown origin: assists in locating occult sources of fever when conventional tests are inconclusive. - Osteomyelitis assessment: differentiates bone infection from other causes of bone pain. - Prosthetic joint evaluation: detects infection around orthopedic implants.

Adverse reactions may occur following intravenous administration of Indium-111 oxine.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Nausea: transient feeling of queasiness. - Flushing: temporary skin reddening. - Headache: mild to moderate intensity. - Transient leukopenia: temporary reduction in white blood cell count. - Mild allergic reaction: rash or itching.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic response requiring immediate medical attention. - Radiation‑induced marrow suppression: prolonged decrease in blood cell production. - Severe hypotension: marked drop in blood pressure post‑infusion. - Infection risk: due to immunosuppression in vulnerable patients. - Pulmonary embolism: rare clot formation related to cell aggregation. - Organ toxicity: rare hepatic or renal impairment.

Prior to administration, clinicians should assess patient suitability and adhere to radiation safety guidelines. - Patient selection: evaluate renal function, allergy history, and prior exposure to radiopharmaceuticals. - Radiation safety: limit cumulative dose and follow institutional radiation protection protocols. - Pregnancy: avoid unless clearly justified, as fetal exposure to ionizing radiation is possible. - Breastfeeding: discontinue nursing for an appropriate period after dosing. - Concomitant myelosuppressive therapy: monitor complete blood counts closely. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 oxine may interact with other agents that affect radiation exposure or blood cell function.

Major Interactions (Avoid): - Therapeutic radioisotopes: co‑administration can lead to excessive radiation burden. - Myelosuppressive agents (e.g., chemotherapy): increase risk of severe marrow toxicity.

Moderate Interactions (Monitor Closely): - Contrast media used in CT: may alter imaging interpretation. - Antihistamines: could mask early signs of an allergic reaction. - Beta‑blockers: may influence distribution of labeled leukocytes. - Immunosuppressants: heightened infection risk when combined with radiolabeling. - Diuretics: potential impact on renal clearance of free indium.